# Zhenya Lindgardt

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/zhenya-lindgardt
Canonical HTML page: https://getyourbrief.com/entity/zhenya-lindgardt

## Timeline

- **2028-01-01**: Runway Horizon — Current capital projected to fund operations through significant commercial milestones.
- **2028-01-01**: Cash Runway Limit — Current capital projected to fund operations through this period across commercial milestones.
- **2026-12-31**: 2026 Target — Goal to reach 15-17 states and operate 5-7 live partner programs.
- **2026-12-31**: Commercial Target — Goal to reach 15-17 states and 5-7 live partner programs.
- **2026-03-18**: Q4 Earnings Call — Management outlines pivot from R&D to commercial scaling and state-level engagement.
- **2026-03-18**: Q4 Earnings Call — Management confirms runway through 2028 and details PRIME study impact.
- **2026-03-18**: Sera Prognostics Commercial Pivot — Announces target to reach 15-17 states and 60% of US births by year-end.
- **2026-03-17**: Meta-Oklo Agreement — Execution of 1.2GW Aurora power campus development in Ohio.
- **2026-03-05**: Ecopetrol Dividend Proposal — Board proposes COP 110 per share dividend representing 50% of net income.
- **2026-01-15**: Oklo Capital Raise — Raises $1.182 billion net through ATM program to fund Aurora projects.
- **2025-12-31**: Fiscal Year End — Sera concludes 2025 with $95.8M cash and successful PRIME study publication.
- **2025-12-31**: Fiscal Year End — Sera concludes 2025 with $95.8M in cash and a narrowed net loss.
- **2025-08-13**: Ecopetrol Production Peak — Reports highest production in a decade at 751,000 boe/d.

## Recent coverage (4 stories, network-wide)

### Strategic Endurance: Q4 Earnings Reveal a New Era for Venture-Scale Publics
2026-03-19 00:18:47 · Sector: startups · Sentiment: Positive · Impact: 6/10 · Sources: 6

The Q4 2025 earnings cycle highlights a critical shift for growth-stage public companies, where massive capital reserves and operational efficiency are being prioritized over immediate revenue. From Oklo's multi-billion dollar infrastructure plays to Sera Prognostics' clinical-milestone focus, the 'Strategic Endurance' model is now the primary driver of market sentiment.
Full story: https://getstartupbrief.com/story/q4-2025-earnings-startup-venture-capital-analysis

### Q4 Earnings: Tech-Infra and Biotech Pivot as Retail Faces Margin Pressure
2026-03-19 00:18:32 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 6

The Q4 2025 earnings cycle reveals a stark divergence between high-growth infrastructure bets and established retail and energy players navigating macroeconomic headwinds. While nuclear energy and biotech firms are securing massive capital for long-term deployments, consumer-facing giants like lululemon are grappling with regional stagnation and tariff-driven margin compression.
Full story: https://getfinancebrief.com/story/q4-2025-earnings-analysis-tech-infra-biotech-retail

### Sera Prognostics Leverages PRIME Study Success for 2028 Commercial Runway
2026-03-19 00:17:38 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 6

Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.
Full story: https://getbiobrief.com/story/sera-prognostics-q4-2025-earnings-prime-study-commercialization

### Sera Prognostics Targets 2028 Runway as PRIME Study Bolsters Commercial Pivot
2026-03-19 00:16:48 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 6

Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.
Full story: https://gethealthbrief.com/story/sera-prognostics-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.